Optibrium™ announced a collaboration with MSD. As part of the collaboration MSD has adopted Optibrium’s StarDrop™ software as a central component of their cheminformatics infrastructure.

Intellia Therapeutics, Inc announced that the first patient has been treated with NTLA-2001, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR).

The seventh annual Movers and Shakers in BioBusiness report highlights 30 examples of resourceful leaders in the UK bioscience sector.

PhoreMost Limited and Oxford Biomedica plc today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.

AMSBIO announce a new rabbit and mouse recombinant monoclonal antibody development service based upon a revolutionary technology platform.

CN Bio today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services. The new toxicity testing services also provide researchers with additional support and bandwidth during the COVID-19 pandemic, when laboratories are not at full capacity.

Porvair Sciences reports on testing that demonstrates how its hydrophilic Vyon® porous plastics exhibit outstanding performance in drug discovery applications due to the high hydrophilic void volume conversion of the materials’ pore structure after a special treatment process.

Registrants to these 2 important online events will be able to listen and learn about the latest innovative sample management products and application solutions that Ziath can provide – directly from the comfort of your own laboratory or office.

Optibrium today announced the launch of Cerella, an Artificial Intelligence (AI) software platform for drug discovery that delivers active learning using advanced deep learning methods.

AMSBIO is launching a new range of human iPSC-derived cells and human iPSC differentiation reagent kits optimized for high-throughput experiments in areas including drug discovery and toxicity screening.